Price cut secures a place for Ipsen’s Cabomeytx on the NHS
Ipsen has cut the price of its kidney cancer Cabometyx to secure its place within the NHS’ routine commissioning stream, helping to over-turn a previous decision that it did not represent value for money.
Read More
